ONO-2506
DrugOnce daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
NCT Number: NCT00229177
The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.
Looking for future studies?
Notify Me20 year–79 year
All sexes
Interventional
Phase 2 / Phase 3
Chugoku Region Facility, Chugoku, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
Time frame: 90 days
Time frame: 30 days
Time frame: 90 days
Ono Pharmaceutical Co., Ltd.
Industry
Controlled Study of ONO-2506 in Patients With Acute Ischemic Stroke
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial DetailsNCT06317194
Brain Diseases, Cardiovascular Diseases
Berkeley, California, United States
View Trial DetailsNCT07208422
Brain Diseases, Cardiovascular Diseases
Kano, Kano State, Nigeria
View Trial DetailsNCT04042584
Brain Diseases, Cardiovascular Diseases
Bordeaux, France
View Trial Details